Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses

Juliet Meir¹, Muhammad Abbas Abid², Muhammad Bilal Abid³,∗

¹ Department of Medicine, Westchester Medical Center, Valhalla, New York
² Department of Hematopathology & Microbiology, The Aga Khan University Hospital, Karachi, Pakistan
³ Divisions of Infectious Diseases and Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin

ABSTRACT
Chimeric antigen receptor T cell (CAR-T) therapy has shown unprecedented response rates in patients with relapsed/refractory (R/R) hematologic malignancies. Although CAR-T therapy gives hope to heavily pretreated patients, the rapid commercialization and cumulative immunosuppression of this therapy predispose patients to infections for a prolonged period. CAR-T therapy poses distinctive short- and long-term toxicities and infection risks among patients who receive CAR T-cells after multiple prior treatments, often including hematopoietic cell transplantation. The acute toxicities include cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. The long-term B cell depletion, hypogammaglobulinemia, and cytopenia further predispose patients to severe infections and abrogate the remission success achieved by the living drug. These on-target-off-tumor toxicities deplete B-cells across the entire lineage and further diminish immune responses to vaccines. Early observational data suggest that patients with hematologic malignancies may not mount adequate humoral and cellular responses to SARS-CoV-2 vaccines. In this review, we summarize the immune compromising factors indigenous to CAR-T recipients. We discuss the immunogenic potential of different SARS-CoV-2 vaccines for CAR-T recipients based on the differences in vaccine manufacturing platforms. Given the lack of data related to the safety and efficacy of SARS-CoV-2 vaccines in this distinctively immunosuppressed cohort, we summarize the infection risks associated with Food and Drug Administration-approved CAR-T constructs and the potential determinants of vaccine responses. The review further highlights the potential need for booster vaccine dosing and the promise for heterologous prime-boosting and other novel vaccine strategies in CAR-T recipients.

INTRODUCTION
Chimeric antigen receptor T-cell (CAR-T) therapy, using autologous T-cells redirected toward a tumor-specific antigen, is a useful treatment modality for patients with relapsed/refractory (R/R) hematologic malignancies [1–3]. The engineered T-cells are transduced with a CAR molecule consisting of an antigen recognition single-chain variable fragment (scFv), a transmembrane domain, and an intracellular signaling domain, CD3ζ. The intracytoplasmic and transmembrane portions of a second-generation CAR T-cell contain signaling domains of costimulatory receptors involved in T-cell activation and durability, including CD3ζ, CD28, 4-1BB, ICOS, and OX40. Later-generation CAR T-cell constructs may contain multiple signaling domains that determine durability, eventual CAR T-cell fate, and metabolism independent of major histocompatibility complex (MHC) restrictions [2].

As of this writing, the US Food and Drug Administration (FDA) has approved several CAR-T constructs directed against CD19 and B-cell maturation antigen (BCMA). These include tisagenlecleucel (tisa-cel; Kymriah) for the treatment of R/R acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL), axicabtagene ciloleucel (axi-cel; Yescarta), and lisocabtagene maraleucel (liso-cel; Breyanzi) for treating R/R DLBCL and other lymphomas that share similar histopathological features, and brexucabtagene autoleucel (brex-cel; Tecartus) for treating R/R mantle cell lymphoma (MCL). More recently, idecabtagene vicleucel (ide-cel; Abecma), directed against BCMA, received FDA approval for the treatment of R/R multiple myeloma (MM) [4–9].

Although CAR-T therapy prolongs the survival of patients with R/R diseases, the associated on-target off-tumor toxicities, particularly infections, limit the effective utilization of...
this curative therapy, CAR-T poses distinctive short- and long-term toxicities and infection risks among patients who receive CAR-T after multiple prior treatments, often including hematopoietic cell transplantation (HCT). CAR-T construct, signaling domains, cytokine release syndrome (CRS), neurotoxicity, and peri-CAR-T interventions confer risk of unique infections in the early period. The long-term B-cell depletion, hypogammaglobulinemia, and cytopenia further predispose patients to severe infections and abrogate the remission success achieved by the living drug.

**RISK OF INFECTIONS IN GENERAL WITH CAR-T THERAPY**

The infection-related data reported thus far are limited to CD19-targeted CAR-T. In a single-center retrospective study, examining 85 axi-cel recipients with large B-cell lymphoma (LBCL) who maintained remission post-CAR-T therapy, 37% of patients developed infections by day+30, of which 13% were severe. Severe infections were associated with CRS, neurotoxicity, tocilizumab and corticosteroid use, and bridging therapy on univariate analysis [10]. The general risks of infection with CAR-T therapy are further discussed at length in the section below titled “INFECTION RISK IN RECIPIENTS OF CAR-T IMMUNOTHERAPY.”

**COVID-19 OUTCOMES IN CELLULAR THERAPY RECIPIENTS**

As of August 1, 2021, SARS-CoV-2 has infected more than 200 million people and caused more than 4 million deaths globally. Patients with cancer are at a particularly higher risk, and those with hematologic malignancies are at the greatest risk of severe COVID-19 and mortality (13% to 39%) [11–17]. HCT and CAR-T recipients are at an even higher risk [18]. A recent study from the Center for International Blood and Marrow Transplant Research registry examining 318 HCT recipients showed a mortality rate of 30% at 30 days after the development of COVID-19. Among allogeneic HCT (alloHCT) recipients, increased mortality risk was associated with age >50 years, male sex, and development of COVID-19 within 1 year of transplantation. Among autologous HCT (autoHCT) recipients, patients who underwent HCT for lymphoma had a higher mortality risk than patients with MM [19]. In addition, lymphopenia (defined as absolute lymphocyte count <300/μL) at the time of COVID-19 diagnosis was associated with a higher mortality risk among HCT survivors. Other studies have shown similarly higher mortality among HCT recipients, with increasing age, presence of active graft-versus-host disease, and development of COVID-19 early after HCT as predictors of mortality [15–17].

In a retrospective study from Italy examining 82 HCT recipients who developed COVID-19, death occurred in 33% of autoHCT recipients and in 35% of alloHCT recipients [15]. Older age, progressive disease status, and diagnosis of acute myelogenous leukemia, non-Hodgkin lymphoma (NHL), or plasma cell neoplasms were associated with inferior survival. The Spanish cohort reported a 45-day overall mortality rate of 17% in 65 alloHCT recipients and 18% in 58 autoHCT recipients [20]. Age >70 years and hypertension were associated with an increased risk of mortality. In a study from New York, that examined 77 patients, the clinical outcomes were more favorable, with 78% overall survival at 30 days [16]. Notably, the alloHCT cohort in that study included only a few patients with active graft-versus-host disease.

The study from New York also included 5 patients with B-cell NHL (B-NHL), who had received CAR-T products directed against CD19, including 4 with axi-cel and 1 with tisa-cel [16]. In another case report, a 73-year-old patient with R/R MM developed severe COVID-19 12 days after receiving CAR-T therapy targeting BCMA [21]. The patient developed persistent viremia for >2 months and eventually died. Postmortem sequencing revealed viral evolution with multiple sequence variants within the host concurrent with significantly diminished humoral and cellular immune responses. Another study that included 2 CAR-T recipients in a cohort of 20 cancer patients confirmed profound immunosuppression and prolonged viral shedding and detected viable virus by cell culture [22]. Another study from the Dana-Farber Cancer Institute examined outcomes in 127 cellular therapy patients treated during the initial COVID-19 surge, including 27 CAR-T recipients. During the study period, 1 patient with DLBCL contracted COVID-19 at 51 days after receiving tisa-cel and died from COVID-19-related complications 121 days after CAR-T infusion [23].

**OVERVIEW OF B CELL DEVELOPMENT**

The risk for infectious pathogens is likely associated with tumor-associated antigen (TAA) and the stage of differentiation at which the antigens are expressed on B-cells. B-cell development begins in the liver, where stromal cells provide cytokines and chemokines to differentiate hematopoietic stem cells into common lymphoid progenitors [24]. With the aid of transcription factors, E2A, and early B-cell factor, common lymphoid progenitor cells differentiate into pro-B-cells [25]. Pro-B-cells then undergo heavy and light chain rearrangement, leading to IgM-expressing immature B-cells [26]. These immature B-cells migrate from bone marrow to spleen and differentiate into mature B-cells, which then differentiate into plasma cells (PCs). Follicular helper T-cells activate B-cells to differentiate into short-lived PCs or enter the germinal center to differentiate into PCs or memory B-cells. These germinal center PCs migrate to the bone marrow to produce specific PCs [27].

**CD19 AND BCMA – ANTIGEN PRODUCTION AND ROLE IN IMMUNITY**

Two vital antigens are expressed on the B-cell surface during the differentiation process. The B-lymphocyte antigen CD19 is a transmembrane protein expressed in follicular dendritic cells (DCs) and all B lineage cells except PCs. CD19 acts as an adaptor protein to recruit cytoplasmic signaling proteins to the membrane and functions within the CD19/CD21 complex to decrease the threshold for B-cell receptor signaling pathways. Owing to its expression on the cell surface of all B-cells, CD19 is a biomarker for B-cell development, as well as for the diagnosis and treatment response of B-cell hematologic malignancies. It also serves as a target for antileukemia and lymphoma immunotherapies.

BCMA, also known as tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a protein encoded by the TNFRSF17 gene. BCMA is expressed on B-cells in the interfollicular region of the germinal center and is preferentially expressed in mature B lymphocytes and on MM cells [28,29]. It plays a significant role in the maturation and differentiation of B-cells into PCs, and its expression is essential for the survival of long-lived PCs [29,30]. Several studies have demonstrated BCMA expression on differentiated PCs in normal lymphoid tissue (bone marrow, lymph nodes, spleen, and tonsils) and lack of expression on naive B-cells and other hematopoietic cells, including neutrophils, macrophages, and T-cells. In addition, BCMA is consistently expressed on malignant PCs, with only limited distribution in normal tissue [31–34]. Up-regulation of BCMA also correlates with disease burden and...
prognosis in MM and serves as a target for antmyeloma immune-engaging platforms [31,35].

CELL SURFACE ANTIGENS AND RISK OF BACTERIAL AND VIRAL INFECTIONS

CD19 is expressed selectively on earlier-stage B-cells and follicular DCs and plays a role in antigen-independent development and immunoglobulin activation of B-cells [36–40]. Unlike BCMA, however, terminal PCs lose CD19 expression [38,39]. Malignant PCs also lack surface CD19 expression [41]. Studies have demonstrated only a weak T cell-dependent humoral response in CD19-deficient mice and humans, owing to the lack of expression of CD19 on PCs [38,42]. Other studies have shown that a mutation in the CD19 gene leads to adequate differentiation of precursor and early B-cells but decreases in memory B-cells, resulting in hypogammaglobulinemia [37]. With the depletion of CD19 on nonmalignant cells, CD19-directed CAR-T recipients could be at higher risk for bacterial infections, particularly in the initial post-CAR-T period.

The globally compromised immune repertoire with BCMA-directed CAR-T could lead to preferentially more viral infections and due to intracellular pathogens compared with more bacterial infections with CD19-directed CAR-T. Thus, patients with R/R MM receiving anti-BCMA CAR-T therapy could be at a notably higher risk of developing severe COVID-19. Consequently, routine reassessment of immune response and booster doses may be necessary.

Although limited, some data are available on BCMA expression in neurons, mainly in the basal ganglia and the cerebellum [43,44]. Although the findings require validation and proof-of-concept, ongoing clinical trials of anti-BCMA CAR-T and bispecific T-cell engagers will highlight any non-T-cell-mediated neurotoxicity related to BCMA expression. Expectedly, a higher level of clinical suspicion should be maintained for the risk of central nervous system infections with anti-BCMA therapy.

HUMORAL AND CELL-MEDIATED IMMUNITY TO VIRAL INFECTIONS

An intricate balance of humoral and cell-mediated immunity protects against viral infections. Humoral immunity is provided by the B-cells that produce antibodies. The protective antibodies neutralize virus and prevent its entry into host cells. Protective immunity is rendered by neutralizing antibodies, the potency and concentration of which are quantified as the titer required to neutralize 50% of viral plaques in an immunofluorescence test (50% inhibitory dilution [ID50]). The neutralizing titers are then correlated with clinical outcomes; for instance, a hemagglutination inhibition titer of 1:40 is thought to provide 50% protection from influenza infection [45].

Macrophages and cytotoxic (CD8+) T-cells eliminate virus-infected cells and constitute cell-mediated immunity [46]. Helper (CD4+) T-cells activate B and CD8+ T-cells. CD4+ T-cell subsets, including Th1 and Th2, orchestrate phagocytosis, cell-mediated immunity, and allergic-type inflammation. Antigen-specific memory B and T-cells persist and provide memory to prevent future infections [47].

In a viral infection, the innate immune response is initiated by antigen-presenting cells, such as macrophages and DCs, which present processed viral peptides to major histocompatibility complex molecules and prime naive antigen-specific T-cells in the secondary lymphoid tissues. Costimulatory molecules and cytokines aid optimal T-cell priming. Immune correlates of protection against SARS-CoV-2 are being explored, and the existing data indicate that a combination of humoral and cell-mediated immunity to SARS-CoV-2 is essential for preventing severe and recurrent illness. Studies have shown robust cell-mediated immune responses in immunocompetent individuals after the SARS-CoV-2 vaccine. The mRNA vaccine has been shown to produce CD4+ and CD8+ T-cell responses, including Th1 cell responses and abundant expression of IFN-γ and IL-2 [48,49]. Similarly, a study examining the recombinant adenovirus vector SARS-CoV-2 vaccine reported increased expression of IFN-γ without an IL-4 response, favoring a Th1 cell response [50]. The kinetics and robustness of immune response to COVID-19 in immunocompetent patients have been reviewed further elsewhere [18,51].

INFECTION RISKS IN RECIPIENTS OF CAR-T IMMUNOTHERAPY

Although there is a dearth of data related to COVID-19 outcomes in CAR-T recipients, there is more evidence related to CAR-T therapy-related infection risk in general. The risk of infections associated with CAR-T depends on various patient- and disease-related factors. The use of a lymphodepletion (LD) chemotherapy regimen, the interval between cell collection and infusion, bridging therapy, CAR T-cell dose, fresh versus cryopreserved cells, single versus fractionated dosing, signaling and costimulatory domains, TAA (CD19 versus BCMA), and duration of lymphopenia and hypogammaglobulinemia are some of the key factors that may confer an increased risk of infections (Figure 1, Table 1) [2,10,52–61]. In addition, CAR-T recipients are more likely to be older (immunosenescence) with a suboptimal performance status, a higher comorbidity burden, and are more likely to have undergone multiple lines of treatment before CAR-T therapy.

Risk of Infections with Signaling Domains CD28 and 4-1BB

The 2 most frequently used signaling domains of costimulatory receptors in modern CAR-T constructs are CD28 and 4-1BB. CD28-based CAR T-cells elicit a robust initial proliferative response and yield effector memory T-cells, whereas 4-1BB costimulation induces a slower and progressive response and endow CAR T-cells with enhanced persistence and central memory differentiation [62–65]. Theoretically, CD28-based CAR-T constructs confer a higher risk of and more frequent and severe CRS compared with 4-1BB-based CAR-T constructs; however, the toxicities need to be compared in head-to-head prospective analyses, as varying CRS grading and treatment algorithms were used in the pivotal trials that led to FDA approval of CD28- and 4-1BB-based CAR-T products. The data from pivotal clinical trials for FDA-approved CAR-T constructs are provided in Table 2.

LD Chemotherapy Regimen and Intensity

In vitro studies have demonstrated that cyclophosphamide (Cy)-based conditioning chemotherapy improves the efficacy and expansion of adoptively transferred tumor-infiltrating lymphocytes [66]. The LD or conditioning regimen decreases the tumor burden and modifies the tumor microenvironment to eliminate the immunosuppressive elements and make it conducive to CAR expansion and persistence of T-cells [67,68]. Several mechanisms prime the tumor microenvironment and alter the tumor phenotype. Decreased production of certain metabolites in tumor cells, increased expression of costimulatory molecules, down-regulation of immunosuppressive elements such as regulatory T-cells and myeloid-derived suppressor cells, and eradication of homeostatic cytokine sinks result in greater availability of IL-2, IL-7, and IL-15 [66,69–71].

The addition of fludarabine (Flu) to Cy has been associated with improved anti-CD19 CAR-T expansion and persistence.
and better clinical outcomes compared with non-Flu-containing LD regimens [72]. Thus, FluCy is the most widely used LD chemotherapy, albeit with varying dosing regimens. LD chemotherapy before CAR-T therapy impacts the efficacy, toxicity, and persistence of infused CAR-T cells; however, the optimal regimen and intensity remain unclear. A higher intensity LD regimen may predispose patients to a higher risk of infections. Clinical data showing a direct association of LD chemotherapy dose with infections are limited but evolving. A recent preliminary report of a prospective trial examining the safety and efficacy of an off-the-shelf CD19-targeting allogeneic CAR-T construct given to 13 patients with R/R NHL showed considerably higher rates of infections and CRS-related adverse events in patients who received an escalated LD regimen compared with those who received a standard LD regimen. Two of 7 patients who received escalated LD developed grade ≥3 infections, compared with none of the 6 patients with infections in the standard LD group [61].

**Figure 1.** Predictors of infections and SARS-CoV-2 vaccine responses in CAR-T recipients: Figure 1, panel A: CAR-T-related factors: Immunity to SARS-CoV-2 is conferred by intricate crosstalk of both antibody and T-cell responses. Prolonged B-cell aplasia, hypogammaglobulinemia, and prolonged cytopenia predispose CAR-T recipients to severe infections. CD28-based CAR-T constructs likely confer a higher risk or more frequent and severe CRS as compared to 4-1BB-based CAR-T constructs and hence a higher incidence for infections. CAR-T targeting CD19 likely results in more bacterial infections, whereas viral infections commonly occur following BCMA-directed CAR-T. Cumulative dosages of corticosteroids and tocilizumab further increase the infection risks and negatively impact vaccine responses. Figure 1, panel B: Peri-CAR-T related factors: The risk of infections and humoral and cellular response to SARS-CoV-2 vaccine with CAR-T depends upon several patient-, disease-related factors, and interventions performed around the period of CAR-T infusion. These include lymphodepletion chemotherapy regimen, the interval between cell collection and infusion, bridging therapy, CAR T-cell dose, and duration of lymphopenia and hypogammaglobulinemia.

**CRS as a Risk Factor for Infections**

Mechanisms of CRS conferring a higher risk of infections

The FDA-approved second-generation CAR-T constructs differ primarily in their costimulatory domains, either 4-1BB-based (tisa-cel, liso-cel, and ide-cel) or CD28-based (axi-cel and brex-cel) CARs [4–9]. This confers a differential risk of CRS, particularly of severe CRS. The immune dysregulation associated with CRS has been linked to the risk of infections. Although the exact mechanisms that incite and perpetuate CRS remain to be elucidated, the hypercytokinemia related to robust expansion of CAR T-cells may lead to immune paralysis, tissue damage, and disruption of the mucosal barrier [73–75]. The production of IL-6 is thought to be critical to the development of CRS. IL-6 signaling is positively correlated with the production of other proinflammatory cytokines and chemokines [75]. In addition, IL-6 activates the differentiation of monocytes and macrophages, inhibits regulatory T-cells, and attracts other immune cells, potentially amplifying CRS [76,77]. Furthermore, severe CRS has been shown to delay
| Factors to be considered                                      | Additional notes                                                                 | Reference |
|---------------------------------------------------------------|-----------------------------------------------------------------------------------|-----------|
| **Disease/tumor-related factors**                             |                                                                                  |           |
| Disease status at CAR-T infusion                              | ↑ risk with disease in remission (likely)                                         |           |
| Prior lines of therapy                                        | ↑ risk with greater prior lines of treatment (cumulative immunosuppression)       | 1         |
| Prior HCT                                                      | Dependent upon the number/types of prior HCT, donor type, allograft source, conditioning regimen, and intensity | 2         |
| Interval between prior HCT and CAR-T                          | ↑ risk with longer interval (likely)                                              |           |
| Time from diagnosis to CAR-T                                  | ↑ risk with longer interval (likely)                                              |           |
| CNS status at diagnosis or at time of CAR-T                   | ↑ risk with CNS involvement (likely)                                             |           |
| **ALL**                                                       |                                                                                  | 3         |
| Cytogenetics risk                                             | ↑ risk with high-risk cytogenetics (likely)                                      |           |
| MRD status at CAR-T infusion                                  | ↑ risk with MRD-negative disease (likely)                                        |           |
| **B-NHL**                                                     |                                                                                  |           |
| Size of largest nodal mass at the time of CAR-T               | ↑ risk with bulky disease                                                       | 4         |
| LDH at the time of CAR-T (or prior to LD)                     | ↑ risk with a higher disease burden                                              | 6         |
| **MM**                                                        |                                                                                  |           |
| Cytogenetics risk                                             | ↑ risk with high-risk cytogenetics (likely)                                      | 3         |
| ISS stage                                                     | ↑ risk with advanced stage and aggressive disease (likely)                       |           |
| Immunochemical subtype                                        | ↑ risk with IgM immune paresis (likely)                                           |           |
| Number and lines of therapy < CAR-T                          | ↑ risk with greater prior lines of treatment (cumulative immunosuppression)     | 5,5       |
| Type of prior treatment (PI, IMID, mAb, SINE)                 | ↑ risk with PIs; ↑ theoretical risk with SINEs                                   | 6,7       |
| **Patient-related factors**                                   |                                                                                  |           |
| Age at the time of CAR-T infusion                             | ↑ risk with older age                                                            | 8         |
| Race/ethnicity                                                | ↑ risk with ethnic minorities (AA, Hispanics, PI)                                | 8,19      |
| BMI                                                           | ↑ risk of infections with higher BMIs                                            | 11,12     |
| KPS                                                           | ↑ risk with poor performance status                                              | 13        |
| HCT-CI (or comorbidities)                                     | ↑ risk with higher burden of comorbidities                                       | 14        |
| **CAR-T related factors**                                     |                                                                                  |           |
| Time from cell collection to CAR-T infusion                  | ↑ risk with shorter interval between apheresis and CAR-T infusion (likely)       |           |
| Prolonged cytopenia                                           | ↑ risk with duration and depth of cytopenia                                      | 5,15-17   |
| Lymphodepleting chemotherapy:                                 | ↑ risk with Cy-based LD chemotherapy (demonstrated in the setting)              | 4,18-22   |

(continued)
References:

1. Kambhampati S, Fakhri B, Sheng Yet al. Infectious Complications of BCMA-Targeted and CD19-Targeted Chimeric Antigen Receptor T-Cell Immunotherapy. Blood 2020; 136:4-5.

2. Vora SB, Waghmare A, Englund JA, Qu P, Gardner RA, Hill JA. Infectious Complications Following CD19 Chimeric Antigen Receptor T-cell Therapy for Children, Adolescents, and Young Adults. Open Forum Infect Dis 2020; 7:ofaa121.

3. Hill JA, Li D, Hay KAet al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood 2018; 131:121-130.

4. Hay KA, Hanafi L-A, Li Det al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy. Blood 2017; 130:2295-2306.

5. Fried S, Avigdor A, Bielorai Bet al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant 2019; 54:1643-1650.

6. Abid H, Wu JF, Abid MB. Risk for infections with selinexor in patients with relapsed/refractory multiple myeloma: a systematic review of clinical trials. Eur J Cancer 2021; 154:7-10.

7. Chen M, Zhao Y, Xu C, Wang X, Zhang X, Mao B. Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies. Annals of Hematology 2018; 97:925-944.

8. Lin RJ, Elko TA, Devlin SMet al. Impact of geriatric vulnerabilities on allogeneic hematopoietic cell transplantation outcomes in older patients with hematologic malignancies. Bone Marrow Transplantation 2020; 55:157-164.

9. Majhail NS, Nayyar S, Santhiabale MeB, Murphy EA, Denzen EM. Racial disparities in hematopoietic cell transplantation in the United States. Bone marrow transplantation 2012; 47:1385-1390.

10. Baker KS, Davies SM, Majhail NSet al. Race and socioeconomic status influence outcomes of unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009; 15:1543-1554.

11. Turbitt WJ, Buchta Rosean C, Weber KS, Norian LA. Obesity and CD8 T cell metabolism: Implications for anti-tumor immunity and cancer immunotherapy outcomes. Immuno Rev 2020; 295:203-219.

12. Mirsoian A, Murphy WJ. Obesity and cancer immunotherapy toxicity. Immunotherapy 2015; 7:319-322.

13. Wudhikarn K, Palomba ML, Pennisi Met al. Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. Blood Cancer J 2020; 10:79.

14. Kittai AS, Gordon MJ, Mian Aet al. Comorbidities Predict Inferior Survival in Patients Receiving CAR T-Cell Therapy for Relapsed/Refractory DLBCL: A Multicenter Retrospective Analysis. Blood 2019; 134:780-780.

15. Wang L, Hong R, Zhou Letc. New-Onset Severe Cytopenia After CAR-T Cell Therapy: Analysis of 76 Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. Front Oncol 2021; 11:702644.

16. Jurlin KR, Hirayama AV, Mullen Eet al. Severe Cytokine Release Syndrome Is Associated With Impaired Hematopoietic Recovery after CD19-Targeted CAR-T Cell Therapy. Blood 2019; 134:3229-3229.

17. Rejeski K, Perez Perez A, Sesques Pet al. CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma. Blood 2021.

18. Gattinoni L, Finkelstein SE, Klebanoff CAet al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 2005; 202:907-912.

19. Lowe KL, Mackall CL, Norry E, Amado R, Jakobsen BK, Binder G. Fludarabine and neurotoxicity in engineered T-cell therapy. Gene therapy 2018; 25:176-191.

20. Ninomiya S, Narala N, Huye Let al. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood 2015; 125:3905-3916.

21. Neelapu SS. CAR-T efficacy: is conditioning the key? Blood 2019; 133:1799-1800.

22. Turtle CJ, Hanafi L-A, Berger Cet al. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Science translational medicine 2016; 8:355ra116-355ra116.

23. Shah BD, Jacobsen CA, Solomon Set al. Preliminary safety and efficacy of PCAR0191, an allogeneic, off-the-shelf CD19-targeting CAR-T product, in relapsed/refractory (r/r) CD19+ NHL. Journal of Clinical Oncology 2021; 39:7516-7516.

24. Muranski P, Boni A, Wrezinsksi Cet al. Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go? Nat Clin Pract Oncol 2006; 3:668-681.
neutrophil engraftment, which may predispose to infections [75,78]. Coupled with the compounded use of immune modulators for its treatment, such as corticosteroids and IL-6 blockade, the immune dysregulation after severe CRS also may impact long-term responses to vaccines [59,79,80].

A single-center study examining the clinical presentation and biomarkers of severe CRS in 133 adult patients who received CD19+ CAR-T therapy showed that 70% of patients developed CRS. Multivariable analysis identified high marrow tumor burden, LD using Cy and flu, higher CAR T-cell dose, thrombocytopenia before LD, and manufacturing of CAR T-cells without selection of CD8+ central memory T-cells as independent predictors of CRS. Severe CRS was characterized by hemodynamic instability, capillary leak, and consumptive coagulopathy. Endothelial dysfunction coincided with severe CRS and was accompanied by high serum biomarkers and endothelium-activating cytokines, such as IL-6 and IFN-γ [81].

Clinical data related to higher infection risk with CRS

CRS severity has been shown to be associated with an increased risk for infections in several studies. A study examining infection density and pretreatment and post-treatment risk factors for infection within the first 3 months among 133 CD19+ CAR-T recipients showed a higher infection density in the first 30 days than between days 31 and 90. Within the first 30 days, bacterial infections were the most common (23% of patients), followed by viral (17%) and fungal (3%) infections. Although ALL, more previous lines of treatment, and higher CAR T-cell doses were associated with a higher infection density, CRS was the sole risk factor independently associated with infections. In addition, 46% of the patients had hypogammaglobulinemia (IgG <400 mg/dL) by day+90 [80]. Similar findings have been reported in patients who received CD19+ CAR-T therapy and developed CRS after T-cell infusion. Park et al. [59] showed that CRS grade ≥3 was significantly associated with infection risk, particularly bloodstream infections, in a phase-I trial of CD19+ CAR-T therapy in 53 patients with B-cell ALL. Within 30 days of CAR-T infusion, 42% of the patients experienced 26 infections (30% bacterial, 10% viral, and 8% fungal).

The costimulatory domain differed in the 2 aforementioned studies, with 4-1BB in the former study and CD28 in the latter. Other studies also have identified severe CRS, prior HCT, LD chemotherapy regimen, and hypogammaglobulinemia as risk factors for subsequent infections with CAR-T [18,52,53,57,58]. Another study examining delayed infections in 60 patients with DLBCL treated with CD19-directed CAR-T also showed that bacterial infections were the most frequent. The cumulative incidence of overall, bacterial, viral, and fungal infections at 1 year were 63%, 57%, 45%, and 4%, respectively [53]. The use of systemic corticosteroids for the management of CRS or immune effector cell-associated neurotoxicity syndrome (ICANS) was shown to be independently associated with an increased risk of infections [53].

CRS in other cellular therapy also confers a higher risk of infection

CRS developing after haploidentical cell transplantation (haploHCT) also has been associated with infections. A single-center study including 78 consecutive adult haploHCT recipients found that severe CRS developing after post-transplantation cyclophosphamide-based haploHCT was independently associated with an increased incidence of infections [78]. The development of severe CRS is associated with a significantly increased risk of nonrelapse mortality, likely driven by increased infections [82].

Hypogammaglobulinemia and Risk of Infection with CAR-T Therapy

CAR-T therapy results in the depletion of normal CD19-bearing cells. The associated hypogammaglobulinemia can be considerably prolonged, predisposes to infections, and impacts outcomes of CAR-T therapy [5,52,53,58,59,80,83]. Furthermore, the durability and response rate to CAR-T correlate with B-cell aplasia. With increasingly sophisticated CAR-T constructs, that harness multiple signaling domains and target multiple TAAs, prolonged B cell aplasia is likely to be an unavoidable, long-term complication in CAR-T recipients for the foreseeable future [2,4,5,7,18,84,85]. However, the incidence and duration of hypogammaglobulinemia as a function of TAA, and its impact on infections and survival and outcomes, have not yet been examined systematically.

CAR T-cell persistence results in delayed B-cell aplasia; hence, hypogammaglobulinemia may be more profound in patients with R/R B-cell ALL treated with tisa-cell than in patients with R/R DLBCL treated with tisa-cell or a-xi-cell. IgG starts to decrease as early as 1 month after CAR T-cell infusion and can remain low for several years [56,57,84]. In clinical practice, CAR-T recipients often exhibit hypogammaglobulinemia for prolonged periods and develop infectious complications [52,53,58]. The existing data are limited to small, single-center studies and are conflicting in correlating hypogammaglobulinemia with distinctive infections. Several studies have reported that an IgG level <400 mg/dL, both pre- and post-CAR-T infusion, is associated with a higher risk of infection. A single-center study evaluating 163 CAR-T recipients identified hypogammaglobulinemia as the most commonly occurring late effect (i.e., event presenting and/or persisting beyond 90 days post-CAR-T infusion) [55]. However, another study in 8 CAR-T recipients suggested a B cell-independent mechanism for the development of long-term humoral immunity. Analysis of bone marrow biopsies after CD19-directed CAR T-cells showed a persistence of antibody-secreting memory PCs for at
| CAR-T Construct | Tisagenlecleucel | Axicabtagene ciloleucel | Lisocabtagene maraleucel | Brexucabtagene autoleucel | Idecabtagene vicleucel | Ciltacabtagene autoleucel |
|-----------------|------------------|------------------------|------------------------|--------------------------|----------------------|-------------------------|
| Abbreviation / commercial product | (tisa-cel)/ Kymriah | (axi-cel)/Yescarta | (liso-cel)/Breyanzi | (brex-cel)/Tecartus | (ide-cel)/Abecma | cilt-cel |
| Clinical trial | JULIET (DLBCL) [5] | ZUMA-1 [7] | TRANSCEND NHL 001 [9] | ZUMA-2 [6] | KartMMA [8] | CARTITUDE-1 [98] |
| Study phase | 2 | 2 | 1 | 2 | 2 | 1b/2 |
| Target antigen | CD19 | CD19 | CD19 | CD19 | BCMA | BCMA (2 epitopes) |
| Costimulatory domains | 4-1BB | CD28 | 4-1BB | CD28 | 4-1BB | 4-1BB |
| Approved indication | R/R ALL in pediatric and young adults; adult R/R DLBCL | Adult R/R LBCL (including DLBCL), high-grade BCL, PMBCL, FL, MCL | Adult R/R MCL | RRMM | RRMM |
| CRS, % | DLBCL: 58 | ALL: 77 | 93 | 42 | 91 | 84 |
| ICANS, % | DLBCL: 21 | ALL: 40 | 64 | 30 | 63 | 18 |
| Infections (any grade), % | DLBCL: 39 | ALL: 43 | 35 (febrile neutropenia) | NR | 32 | 69 |
| Infections (grade ≥ 3), % (n/N) | DLBCL: 20 | ALL: 24 | 31 (febrile neutropenia) | 12 | 3 (2/74) | 22 |
| Sepsis, % (n/N) | NR | NR | <1 (1/269) | 3 | 2 (2/128) | 4 |
| Steroid utilization, % (n/N) | DLBCL: 10 | ALL: 13 | 27 | 10 (26/269) (CRS) | 22-38 | 15 |
| Tocilizumab utilization, % (n/N) | DLBCL: 24 | ALL: 48 | 43 | 18 (48/269) (CRS) | 26-59 | 52 |
| Bridging therapy, % | DLBCL: 92 | Not allowed in ZUMA-1 trial (used in real-world practice) | 59 | 37 | 88 | Allowed |
| Median CAR T cell dose | 3.1 £ 10^6 cells/kg | 2 £ 10^6 cells/kg | 50, 100, 150 £ 10^6 cells/kg | 2 £ 10^6 cells/kg | 150, 300, 450 £ 10^6 cells/kg | Target dose 0.75 £ 10^6 cells/kg |
| LD chemotherapy | Flu 25 mg/m^2 £ 3 d + Cy 250 mg/m^2 £ 3 d or B 90 mg/m^2 £ 2 d | Flu 30 mg/m^2 £ 3 d + Cy 500 mg/m^2 £ 3 d | Flu 30 mg/m^2 £ 3 d + Cy 500 mg/m^2 £ 3 d | Flu 30 mg/m^2 £ 3 d + Cy 500 mg/m^2 £ 3 d | Flu 30 mg/m^2 £ 3 d + Cy 300 mg/m^2 £ 3 d |

MCL indicates mantle cell lymphoma; PMBCL, primary mediastinal B cell lymphoma; CR, complete response; sCR, stringent CR; PFS, progression-free survival; NR, not reported; ICANS, immune effector cell-associated neurotoxicity syndrome; FL, follicular lymphoma; PBMC, peripheral blood mononuclear cells; B, bendamustine.

* As of this writing, the US FDA has granted priority review to the biologics license application for cilt-cel.

** A CAR-T construct with 2 BCMA-targeting single-domain antibodies.

1 Per Penn criteria.

2 CRS was graded by Lee et al. [74] and ICANS by CTCAE v5.0 (in phase 1b). CRS and ICANS were graded by ASTCT criteria (in phase 2). Lee et al. [74] and CTCAE v5.0 were mapped to ASTCT for CRS and ICANS, respectively.

** Given for CRS. Corticosteroid and tocilizumab utilization increased with increasing CAR T cell dose.
least 25 months after CAR-T infusion despite the absence of CD19\(^+\) and CD20\(^+\) B-cells [54]. Similarly, another study showed a preserved antiviral humoral immune response and a low incidence of viral infections after 90 days in 39 CAR-T recipients [86].

**Prolonged Cytopenia and Risk of Infection**

Prolonged cytopenia is a common complication in CAR-T recipients and limits further treatment options, including accrual into clinical trials. Hematologic toxicities, particularly beyond 30 days after CAR-T infusion, remain unexplored. A single-center study of 76 patients with R/R ALL enrolled in phase 1/2 clinical trials of CAR-T targeting CD19, CD22, and CD19/22 showed that 70% of patients developed new-onset severe neutropenia (<0.5 \(\times\) 10\(^9\)/L), 53% developed severe anemia (<60 g/L), and 48% developed severe thrombocytopenia (<20 \(\times\) 10\(^9\)/L) [87]. The severity of CRS was independently correlated with neutrophil recovery. In another single-center study, most of the 35 evaluable patients with ALL and lymphoma (14 pediatric and 21 adults) enrolled in a phase 1b/2 study developed hematologic toxicities following CD19\(^+\) CAR-T infusion [88]. Twenty-eight responding patients (97%) developed neutropenia (<1.5 \(\times\) 10\(^9\)/L), 21 (72%) developed severe neutropenia (<0.5 \(\times\) 10\(^9\)/L), and 8 (28%) developed severe thrombocytopenia (<50 \(\times\) 10\(^9\)/L). There was a non-statistically significant correlation between severe hematologic toxicity and grade \(\geq 2\) CRS [88]. Similarly, another single-center study including 125 patients who received CD19\(^+\) CAR-T for various clinical indications indicated CRS grade as independently associated with impaired hematopoietic recovery after CD19\(^+\) CAR-T therapy [89].

More recently, a large multicenter analysis examined predictive biomarkers of hematologic toxicity and aimed to develop a predictive model (CAR-HEMATOX) to allow risk-adapted management [90]. The analysis included 258 patients receiving axi-cel or tisa-cel for R/R DLBCL and showed profound incidence and/or severity of CRS and ICANS via induction of proinflammatory cytokine secretion from monocytes and macrophages [76,77].

To that end, a small single-center study examined the impact of G-CSF in axi-cel recipients with R/R DLBCL. Seven patients (31.8%) received G-CSF at the physician’s discretion. Although the median duration of neutropenia after LD chemotherapy was significantly shorter in the patients who received G-CSF (filgrastim) compared with those who did not (5 days versus 15 days; \(P = .016\)), there were no differences in the incidence and severity of infection based on G-CSF use. Interestingly, although there was no significant difference in the incidence of CRS or ICANS between the 2 groups, CRS severity was significantly greater in the patients who received filgrastim (\(P = .042\)) [96].

In another single-center study examining 70 recipients of axi-cel and tisa-cel with R/R DLBCL, 42 (60%) received prophylactic G-CSF and the other 28 (40%) did not receive G-CSF [97]. Although there was no difference between the 2 groups in terms of duration of neutropenia and infections, the patients in the G-CSF group were older (63 years versus 50 years; \(P = .002\)) and had a lower neutrophil count at day+0 as well as at day+5. Most patients in the study experienced grade 1-2 CRS, and there was no difference between the 2 groups in terms of incidence and severity of CRS. Similarly, 30% of the patients experienced ICANS, with no significant difference between the 2 groups [97].

Overall, the role of recombinant G-CSF in aiding neutrophil recovery in the CAR-T setting remains unexplored. Prospective studies are needed to examine the potential of G-CSF in preventing infectious complications after CAR-T versus the risk of greater on-target-off-tumor toxicities.

**BCMA-Directed CAR-T and Risk of Infection**

The pivotal phase-II KarMMA trial examined the safety and efficacy of ide-cel (bb2121; Abecma), a 4-1BB-based CAR-T construct directed against BCMA in patients with R/R MM previously treated with at least 3 prior lines of treatment [8]. The toxicity and safety endpoints are shown in Table 2. In terms of infectious complications, within 8 weeks of CAR-T infusion, 25% of the patients developed an infection due to an unspecified pathogen, 16% had a bacterial infection, 15% had a viral infection, and 7% had a fungal infection. The frequency of infections was increased between 8 weeks and 6 months after CAR-T infusion, with 40% of the infections due to an unspecified pathogen, 21% viral, and 3% each bacterial and fungal infections.

The FDA has also granted priority review to the biologic license application for another CAR-T product for treating patients with R/R MM who had received \(\geq 3\) prior regimens. Ciltacabtagene autoleucel (cilta-cel) has 2 BCMA-targeting single-domain antibodies and was examined in the phase 1b/2 CARTITUDE-1 study (ClinicalTrials.gov identifier NCT03548207). Ninety-five percent of the patients developed CRS, including 4% with grade 3/4 CRS. Fifty-eight percent of the patients developed infections, including 20% with severe infections (grade \(\geq 3\)) and 4% with sepsis (Table 2) [98].

**Risk for Infections with Target Tumor Antigen CD19 versus BCMA**

The evolving data described above suggest that CAR-T targeting CD19 likely results in more bacterial infections, whereas viral infections could theoretically occur more commonly following BCMA-directed CAR-T, along with a generally increased risk for overall infections and diminished vaccine responses. This selective predilection for viral infections in a BCMA-directed CAR-T construct possibly stems from the indigenous immunologic properties of the antigen and cell surface...
expression. BCMA is selectively expressed on malignant PCs, normal PCs, and some mature B-cells and has an active role in the differentiation of B-cells into PCs [31,99–101]. The preferential susceptibility to viral infections in the setting of BCMA-directed CAR-T immunotherapy was illustrated in a patient who initially had a decline in plasma SARS-CoV-2 virus with antiviral treatment but ultimately succumbed to recurrent viremia at 71 days following the initial diagnosis [21].

The differential risk of infections has been demonstrated in a single-center retrospective analysis that examined infection outcomes up to 1 year after anti-BCMA- and -CD19-directed CAR-T therapy. Of the 104 patients included in the study, 55 (53%) had R/R MM and received BCMA+ CAR-T, with a median of 6 prior lines of therapy, and 49 had NHL (47%) and received CD19+ CAR-T, with a median of 3 prior lines of therapy. Almost all patients were receiving antimicrobial prophylaxis at the time of CAR-T infusion and did not exhibit severe lymphopenia, neutropenia, or hypogammaglobulinemia prior to LD. There were significant differences in the incidence of viral and bacterial infections between the recipients of BCMA CAR-T and recipients of CD19 CAR-T. The BCMA cohort had 19 bacterial infections (40%), compared with 29 bacterial infections (73%) in the CD19 cohort (P = .005), and had 25 viral infections (53%) compared with 8 viral infections (20%) in the CD19 cohort (P = .002). Fungal infection rates were comparable in the BCMA and CD19 cohorts (3 [6%] versus 3 [8%]; P = 1). The BCMA cohort had a higher rate of respiratory infections (68% versus 50%; P = .1), whereas the CD19 cohort had higher rates of bloodstream infections (15% vs 2%; P = .05) and gastrointestinal infections (10% versus 0%; P = .04). Again, corticosteroid use (incidence rate ratio, 1.6; 95% confidence interval, 1.1 to 2.5; P = .03) and post-CAR-T hypogammaglobulinemia (IgG <600) (incidence rate ratio, 2.1; 95% confidence interval, 1.2 to 3.9; P = .02) were associated with increased of infections, after adjustment for time periods [102].

**Risk of Infections with Underlying Diseases and Treatment**

In addition to the TAA, the underlying disease for which CAR-T therapy is indicated further determines the infection risk. The conditioning regimen and intensity, prior treatment regimens, prior receipt of cellular and immunotherapy, the interval between last treatment and CAR-T, as well as disease status at the time of CAR-T also contribute to the cumulative risk of infection after CAR-T. For instance, the duration and depth of neutropenia determine overall infection risk in patients receiving multiagent cytotoxic chemotherapy, such as in acute leukemia and lymphoma. Further, natural killer cell- and T-cell-mediated cytotoxicity is impaired with patients with ALL and is worse in patients with T-ALL compared with those with B-ALL [103]. Patients with chronic lymphoblastic leukemia (CLL) and MM have an inherent predisposition to infections associated with hypogammaglobulinemia and compromised humoral immunity [104–106]. Patients with MM are at especially higher risk of bacterial and viral infections due to a globally compromised immune system [107,108]. These patients may be at a particularly higher risk for severe COVID-19, as well as suboptimal vaccine responses.

The addition of monoclonal antibodies, immunomodulators, and small molecules to the backbone of frontline regimens further compounds the risk of distinctive infections. For instance, viral reactivation may occur following tyrosine kinase inhibitors, Janus kinase inhibitors, and monoclonal antibodies, and there is an increased risk of pneumonia due to *Pneumocystis jirovecii* with purine analogs, *in vivo* T-cell-depleting agents, corticosteroids, and phosphatidylinositol 3-kinase inhibitors.

**COMMON SARS-COV-2 VACCINE PLATFORMS**

Vaccine development against SARS-CoV-2 has used several platforms, including inactivated, protein subunit, replication-incompetent viral vector-based, and nucleic acid-based platforms [109]. The nucleic acid vaccine platform has been most widely used to develop the SARS-CoV-2 vaccine due both to the rapidity of large-scale manufacturing and to early data demonstrating considerable efficacy. Nucleic acid vaccines mimic natural infection with endogenous antigen production and elicit strong T- and B-cell responses while being noninfectious. The mRNA vaccines are preferred over DNA and other vaccine platforms as mRNA is transient, avoids antivector immunity, and is delivered to the cytosol, preventing the risk of host genome integration [110].

Both mRNA vaccines used in the United States—BNT162b2, developed by Pfizer and BioNTech, and mRNA-1273, developed by Moderna—are lipid nanoparticle-formulated nucleoside-modified mRNA vaccines. The vaccines encode the SARS-CoV-2 full-length spike protein and are given either as a 2-dose regimen 21 days apart (for BNT162b2) or 28 days apart (for mRNA-1273) [111–113].

Both mRNA vaccines provide adequate protection against symptomatic COVID-19 that is mediated by a combined humoral and cellular immune response [48,114]. Clinical trials have demonstrated humoral immune response with antiprotein antibody titers remaining above convalescent levels after the second vaccine dose [115]. Cellular immune studies also have shown expansion of spike-specific CD8+ and Th1 subtype CD4+ T-cell responses, with a high fraction producing IFN-γ [49]. Longitudinal serologic studies and immune kinetics are awaited.

**CURRENT RECOMMENDATIONS FOR SARS-COV-2 VACCINATION FOR CANCER PATIENTS**

The efficacy and safety of SARS-CoV-2 vaccines have not been examined in immunocompromised patients, because these patients were excluded from clinical trials. Although all cancer patients should be considered “highly prioritized,” the optimal dosing and timing for COVID-19 vaccination remain elusive in this population. Expert opinion of a committee of the Society for Immunotherapy of Cancer recommends that cancer patients receiving immunotherapy should receive SARS-CoV-2 vaccination [116]. The American Society of Clinical Oncology also recommends that all cancer patients receive SARS-CoV-2 vaccination unless otherwise contraindicated by the Centers for Disease Control. The American Society of Transplantation and Cellular Therapy, American Society of Hematology, and National Comprehensive Cancer Network currently recommend the administration of mRNA SARS-CoV-2 vaccines as early as 3 months following CAR-T [17,58,117,118]. Further recommendations related to vaccines in general in the preand post-CAR-T period are outlined elsewhere [58].

These guidelines are based on evidence demonstrating efficacy and safety in the general population and acknowledge that efficacy may be reduced among recipients of cellular therapy compared with the general population. This is further compounded by the novelty of the mRNA vaccine platform (with a dearth of longitudinal data) and lack of established anti-SARS-CoV-2 spike binding (anti-S IgG) and neutralizing antibody titers even in the general population. Furthermore, the level of humoral response that correlates with clinical protection remains unknown. A suboptimal response to the SARS-
CoV-2 vaccine has been demonstrated in patients with advanced hematologic malignancies [51]. Moreover, the durability of the immune response and the correlation between in vitro assays and overall vaccine efficacy in immunocompromised patients are yet to be determined.

CURRENT STATE OF SARS-COV-2 VACCINE RESPONSES IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES

Evolving data suggest that patients with hematologic malignancies may have a diminished immune response to the SARS-CoV-2 vaccine [119]. Underlying diseases, overall state of immunosuppression, remission status, receipt of active treatment, and immune reconstitution profile may impact the response (Table 1). Diminished vaccine responses have been described in patients with CLL and MM. B-cell depletion, active treatment with BTK inhibitors, and IgA deficiency have been associated with an inadequate humoral response [120–123]. In the largest study of patients with hematologic malignancies reported to date, comprising 1455 patients, seroprotective antibodies were analyzed 14 days after the second dose of mRNA vaccine, and the data showed superior immune responses to both mRNA vaccines in patients with leukemia, MM, and Hodgkin lymphoma compared with those with B-cell NHL subtypes [124]. These suboptimal response rates to mRNA-based vaccines in patients with hematologic malignancies are in congruence with those demonstrated previously with other nonlive vaccines against a variety of illnesses [125–127].

DATA ON VACCINE RESPONSE IN CAR-T RECIPIENTS AND ADDITIONAL IMMUNE CONSIDERATIONS

In addition to concerns related to suboptimal efficacy, CAR-T recipients theoretically could have an elevated risk of immune-mediated toxicity. Evidence in immunocompetent individuals have demonstrated robust release of cytokines, including IFN-γ, TNF, IL-1, IL-2, and IL-12, and hemophagocytic lymphohistiocytosis, in addition to the production of neutralizing antibodies and virus-specific CD4+ and CD8+ T-cells [48,128,129]. In addition, the incidence of cytopenia and immune-mediated thrombocytopenia, reported in healthy subjects, also needs to be explored prospectively in CAR-T recipients [130,131]. Data are now evolving related to the immune response to the SARS-CoV-2 vaccine. A prospective single-center study examined serologic and cellular immune responses in a cohort of alloHCT and CAR-T recipients who received BNT162b2 mRNA COVID-19 vaccine. Seroprotective antibodies were analyzed in 14 CAR-T recipients who had maintained remission after CAR-T infusion at 7 to 14 days after the second vaccine dose with an immunoassay that detected qualitative and semiquantitative IgG to SARS-CoV-2 spike protein receptor-binding domain (RBD). Antispike cellular response was evaluated using the ELISPOT assay for the detection of peptide-induced IFN-γ and IL-2 secretion. Positive serology was detected in 5 patients (36%), and ELISPOT was positive in 6 patients (50%). Three patients had complete B-cell aplasia, all 3 of whom were CAR-T recipients. As expected, B-cell reconstitution correlated with positive serology compared with those with B-cell aplasia (66% versus 11%; P = .025). In subgroup analyses, the ELISPOT results correlated with the CD4+/CD8+ ratio, whereas the numbers of CD19+, CD4+, and CD8+ cells did not significantly correlate with the probability of positive test results. Interestingly, a higher number of CD19+ cells was associated with a positive humoral response to the vaccine in a multivariate analysis of the entire study cohort, in addition to female sex and a longer time from infusion of cells. Even though the study reported an overall in vitro response of 57% among CAR-T recipients, it is noteworthy that humoral immune response was observed only in 36% of the patients, and that only one-half of those patients had evidence of cellular response. Although there were no grade 3–4 nonhematologic adverse events, 4 patients in the entire cohort of alloHCT and CAR-T recipients (5%) developed grade 3 or 4 thrombocytopenia (n = 3) or neutropenia (n = 1) [132].

Another single-center retrospective study examined humoral immune response to SARS-CoV-2 vaccines (predominantly mRNA-based) in 130 patients, including 14 CAR-T recipients. The study used an enzyme immunoassay that correlated with neutralizing immunity and tested for antibodies against the S1 domain of the spike protein. Positive serology was detected in only 11% of the CAR-T recipients. The seropositivity rate was considerably diminished in patients who had received corticosteroids and those who had undergone CAR-T infusion within 6 months of vaccination [133]. In the largest study examining patients with hematologic malignancies reported to date comprising 1455 patients, seroprotective antibodies were analyzed in a small cohort (n = 12) of CAR-T recipients at 14 days after the second mRNA vaccine dose with an immunoassay that detected semiqualitative IgG to SARS-CoV-2 spike protein RBD [124]. The vaccine responses differed considerably in the CAR-T recipients and depended on the TAA and the underlying disease. Although only 1 of 7 CD19+ CAR-T recipients had a positive antibody response to the vaccine, 4 of 5 patients with MM who had received BCMA+ CAR-T or CD138+ CAR-T exhibited a robust humoral response. Interestingly, the 1 CD19+ CAR-T recipient who responded positively had relapsed CLL immediately before the mRNA vaccination. Also, the 1 BCMA+ CAR-T recipient who responded negatively underwent immune analysis at 14 days after the second mRNA vaccine dose, and the negative result was likely due to insufficient time to generate an antibody response [124]. Considering that B-cell aplasia is a clinical surrogate marker of CAR-T persistence, the robust antibody response in patients with MM may forecast a lack of durability of BCMA+ CAR-T. Longitudinal data related to CAR-T efficacy as well as vaccine responses in CAR-T recipients are awaited.

The foregoing analyses were heterogeneous and limited by low statistical power. Nonetheless, they indicate that humoral responses are substantially diminished in CAR-T recipients and may be driven by the underlying disease and immunocompromising potential of the treatment. These results must be interpreted with caution, given the limitations of small sample sizes, differences in immunoassays, and lack of standard definitions and clinical correlates of SARS-CoV-2 immune response.

IMMUNOSUPPRESSED MILIEU AS A DRIVER FOR MUTATIONAL SARS-COV-2 VARIANTS

Immunocompromised patients are at increased risk for shedding of the replication-incompetent virus [22,51]. Patients with hematologic malignancies undergoing active treatment, particularly B-cell-depleting therapy such as CAR-T, are at a higher risk for prolonged viral shedding. Prolonged use of corticosteroids has been shown to impact viral kinetics in a similar manner. The differential pattern of viral receptor expression and tropism in immunocompromised patients have been reviewed elsewhere [51,134]. Several recent reports have suggested that SARS-CoV-2 variants of concern, with greater transmissibility and pathogenicity, can arise during a protracted course of COVID-19 [135,136]. Multiple mutations
result in the generation of clinical and public health concern variants. These mutations predominate in the spike protein, which is the prime target of the protective antibody response and mediates viral entry.

POTENTIAL STRATEGIES TO BOOST VACCINE RESPONSE IN CAR-T RECIPIENTS

Additional vaccine doses are likely needed in patients with profoundly suppressed humoral immunity and a high cumulative risk of severe infection (Table 1). Early studies have demonstrated the feasibility of CARs and CARs X T cells that do not lead to B-cell aplasia and thus have the potential for a minimal impact on humoral immunity [137]. Meanwhile, the timing and intensity of corticosteroid use for the prevention and treatment of CAR-T toxicities should be reviewed, given the potential for diminished immune responses [138]. Accumulating evidence related to the heterologous prime boost with alternate vaccine technologies also shows promise [139,140]. Initial studies have shown that sequential immunization with adenovirus vectored vaccine and inactivated, recombinant subunit, and mRNA vaccine administration results in higher levels of neutralizing antibodies, more potent humoral immune responses, and greater T-cell reactivity [141]. However, longitudinal studies are needed to determine the optimal sequence, vaccine platform, and timing to establish safety and reduce vaccine-associated reactivity in profoundly immunosuppressed CAR-T recipients. Evidence from the SARS-CoV-1 epidemic showed significantly greater durability with memory T-cell response compared with antibodies [47]. The results of prospective mechanistic studies, such as Center for International Blood and Marrow Transplant Research study SC21-07/BMT-CTN 2101, are awaited [46,142-145]. Furthermore, long-acting monoclonal antibodies or small molecules potentially resistant to current SARS-CoV-2 mutations will need evaluation in prospective studies of cellular therapy recipients. In addition, halting active viral replication with antiviral agents to prevent the development of mutations remains an unmet need.

FUTURE DIRECTIONS

Immunity to SARS-CoV-2 is conferred by intricate crosstalk of both antibody and T-cell responses. Insight into both responses is needed for an optimal understanding of protection in this vulnerable patient group. Longitudinal serologic and cellular studies are essential to understand the duration of immunity and to address whether revaccination or boosting is required and whether this is contingent on the TAA that the CAR T cells are designed to target. Telemedicine should be incorporated at the core of long-term follow-up to minimize the exposure of immunosuppressed patients to the hospitals and the community. Until the data become available, the risk of nosocomial transmission should be minimized by vaccinating all healthcare workers caring for patients with hematologic malignancies, and strict mitigation strategies should remain in place at all cancer centers.

ACKNOWLEDGMENTS

The authors thank Dr. Parameswaran N. Hari for his encouragement and review of the manuscript. He was not compensated.

Financial disclosure: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflict of interest statement: There are no conflicts of interest to report.

Authorship statement: J.M. and M.A.A. contributed equally to this work and are to be considered co-first authors. M.B.A. conceived of the idea, performed the literature search, and wrote the manuscript. M.B.A. and M.A.A. contributed to tables and figures. All authors provided critical input and final approval for the manuscript.

REFERENCES

1. June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379:64–73.
2. Abid MB, Shah NN, Maatman TC, Hari PN. Cut microbiome and CAR-T therapy. Exp Hematol Oncol. 2019;8:31.
3. Kuehn BM. The promise and challenges of CAR-T gene therapy. JAMA. 2017;318(2):2157–2159.
4. Maude SL, Laericher TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439–448.
5. Schurer SJ, Bishop MR, Tarn CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45–56.
6. Wang M, Munoz J, Cloy A. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382:1331–1342.
7. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–2544.
8. Munsli NC, Anderson Jr LD, Shah NH, et al. Idecabtagene vilcelucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705–716.
9. Abramson JS, Palomba ML, Gordon LJ, et al. Lisoctagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839–852.
10. Logue JM, Zuccetti E, Bachmeier CA, et al. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Haematologica. 2021:106:978–986.
11. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancer Oncol. 2020;21:335–337.
12. Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10:783–791.
13. Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395:1907–1918.
14. Mehta V, Goel S, Kaborrii R, et al. Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer Discov. 2020;10:935–941.
35. Tai YT, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma.

32. Tai YT, Mayes PA, Acharya C, et al. Novel anti-B-cell maturation antigen therapy for multiple myeloma. Clin Cancer Res. 2013;19:2048–2060.

31. Carpenter RO, Evbuomwan MO, Pittaluga S, et al. B-cell maturation antigen-directed CAR T-cell therapy for multiple myeloma. Blood. 2020;136:3136–3143.

39. Haas KM, Tedder TF. Role of the CD19 and CD21/35 receptor complex in B cell biology and beyond. Nat Rev Immunol. 2015;15:1187–1199.

37. van Zelm MC, Reisli I, van der Burg M, et al. An antibody-depleting strategy towards immune competence. Trends Immunol. 2019;40:577–589.

33. Osorio C, Chacon PJ, White M, et al. Selective regulation of axonal growth from developing hippocampal neurons by tumor necrosis factor superfamily member APRIL. Mol Cell Neurosci. 2019;54:105–116.

36. Chung JB, Silverman M, Monroe JG. Transitional B cells: step by step. Immunology. 2014;142:3138–3138.

38. Chung JB, Silverman M, Monroe JG. Transitional B cells: step by step. Immunology. 2014;142:3138–3138.

34. Mahmoud MS, Fujii R, Ishikawa H, Kawano MM. Enforced CD19 expression in non-Hodgkin lymphoma. Mol Cell Biol. 2005;25:1734–1740.

32. Tai YT, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. Clin Cancer Res. 2013;19:2048–2060.

31. Carpenter RO, Evbuomwan MO, Pittaluga S, et al. B-cell maturation antigen-directed CAR T-cell therapy for multiple myeloma. Blood. 2020;136:3136–3143.

39. Haas KM, Tedder TF. Role of the CD19 and CD21/35 receptor complex in B cell biology and beyond. Nat Rev Immunol. 2015;15:1187–1199.

37. van Zelm MC, Reisli I, van der Burg M, et al. An antibody-depleting strategy towards immune competence. Trends Immunol. 2019;40:577–589.

33. Osorio C, Chacon PJ, White M, et al. Selective regulation of axonal growth from developing hippocampal neurons by tumor necrosis factor superfamily member APRIL. Mol Cell Neurosci. 2019;54:105–116.

36. Chung JB, Silverman M, Monroe JG. Transitional B cells: step by step. Immunology. 2014;142:3138–3138.
82. Imus PH, Blackford AL, Bettinotti M, et al. Severe cytokine release syn-
 drome after haploidentical peripheral blood stem cell transplantation. 
Biol Blood Marrow Transplant. 2019;25:2431–2437.
83. Haidar C, Dorrinne K, Farah B, Bogdanovich T, Nguyen MH, Samanta P. 
Invasive mold infections after chimeric antigen receptor-modified T-cell 
therapy: a case series, review of the literature, and implications for pro-
phyaxis. Clin Infect Dis. 2020;71:672–676.
84. Park JH, Riviere I, Gonen M, et al. Long-term follow-up of CD19 CAR ther-
apy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449–459.
85. Shah NN, Johnson BD, Schneider D, et al. Bispecific anti-CD20, anti-CD19 
CAR T cells for relapsed B-cell malignancies: a phase I dose escalation 
and expansion trial. Haematol. 2020;195:1341–1349.
86. Hill JA, Krantz EM, Hay KA, et al. Durable prevention of antiviral 
autoimmune effects in CD19-directed chimeric antigen receptor T-cell 
immunotherapy. Blood Adv. 2019;3:3929–3941.
87. Wang L, Hong R, Zhou L, et al. New-onset severe cytopenia after CAR-T cell 
therapy: analysis of 76 patients with relapsed or refractory acute lymphoblastic leukemia. Front Oncol. 2021;11:702644.
88. Fried S, Avigdor A, Bielorai B, et al. Early and late hematologic toxicity 
following CD19 CAR T cells. Bone Marrow Transplant. 2019;54:1643– 
1650.
89. Juluri KR, Hirayama AV, Mullane E, et al. Severe cytokine release syn-
drome in patients with relapsed cryptococcosis with CNS involvement?
90. Polack FP, Thomas SJ, Kitchin N, et al. Safety, immunogenicity, and effi-
cacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021;383:239–250.
91. Ranganathan R, Shou P, Ahn S, et al. CAR T cells targeting human immu-
noglobulin light chains eradicate mature B-cell malignancies while 
sparing a subset of normal B cells. Clin Cancer Res. 2021. https://doi.org/
92. Sachdeva M, Duchateau P, Depil S, Poirot L, Valton J. Granulocyte-macro-
phage colony-stimulating factor inactivation in CAR T-cells prevents 
monocyte-dependent release of key cytokine syndrome release 
mediators. J Biol Chem. 2019;294:5430–5437.
93. Mehta HM, Malandra M, Corey SJ. G-CSF and GM-CSF in neutropenia. 
J Biol Chem. 2015;–1349.
94. Verneux L, Fournet J, Nauta A, et al. Safety and immunogenicity of two 
RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020;383:2439–2450.
95. Rupin LG, Levine MS, Ljungman P, et al. 2013 IDSA clinical practice guide-
line for vaccination of the immunocompromised host. Clin Infect Dis. 
2014;58:309–318.
96. Cordonnier C, Einarsdottir S, Cseso S, et al. Vaccination of haemopoietic 
stem cell transplant recipients: guidelines of the 2017 European Confer-
ence on Infections in Leukaemia (EICL 7). Lancet Infect Dis. 2019;19: 
e200–e212.
97. Polack FP, Thomas SJ, Kitchin N, et al. Safety, immunogenicity, and effi-
cacy of the BNT162b2 mRNA Covid-19 vaccine in patients with chronic lymphocytic leu-
kaemia. Lancet J Cancer. 2021;11:136.
98. Herishanu Y, Avioli I, Aharon A, et al. Efficacy of the BNT162b2 mRNA 
COVID-19 vaccine in patients with chronic lymphocytic leukemia. 
Blood. 2021;137:3165–3173.
99. Bird S, Panopoulos A, Shee RL, et al. Response to first vaccination against 
SARS-CoV-2 in patients with multiple myeloma. Lancet Haematol. 
2021;8:e389–e392.
100. Wang Y, Alimadadi A, Johnson PA, et al. Safety, immunogenicity, and ef-
cacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leu-
kaemia (CLL). Leukemia. 2021;35:737–746.
101. Lee EJ, Cines DB, Gernsheimer T, et al. Thrombocytopenia following 
COVID-19 testing in patients with cancer. Am J Hematol. 2021;53:1726– 
1737.
102. Valenzuela-Vazquez L, Ruiz-Enriquez JC, Sanchez-Herrera J, et al. Func-
tional characterization of NK cells in Mexican pediatric patients with acute lymphoblastic leukemia: report of the Mexican Inter-
tergroup for the Identification of the Causes of Childhood Leuke-
emia, PlO One. 2020;15: e0227314.
103. Chen M, Zhao Y, Xu C, Wang X, Zhang X, Mao B. Immunomodulatory 
drugs and the risk of serious infection in multiple myeloma: systemic 
review and meta-analysis of randomized and observational studies. An-
n Hematol. 2018;97:925–944.
104. Abid H, Wu JF, Abid MB. Risk for infections with se.lenox in patients 
with relapsed/refractory multiple myeloma: a systematic review of clini-
cal trials. Eur J Cancer. 2021;154:7–10.
105. Blijmark C, Holtzberg M, Mekkes BH, et al. Multiple myeloma and infec-
tions: a population-based study on 9253 multiple myeloma patients. 
Haematologica. 2015;100:107–113.
106. Chang L, Goodell D, Moss P. Immunodeficiency and immunotherapy in 
multiple myeloma. Br J Haematol. 2007;138:563–579.
138. Vormehr M, Lehar S, Kranz LM, et al. Dexamethasone premedication suppresses vaccine-induced immune responses against cancer. Oncocommunology. 2020;9:1758004.

139. Hillus D, Schwarz T, Tober-Lau P, et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Lancet Respir Med. 2021; S2213-2600(21)00357-X; https://doi.org/10.1016/S2213-2600(21)00357-X. Epub ahead of print. PMID: 34391547; PMCID: PMC8360702. Accessed 15 August 2021.

140. Hammerschmidt SI, Bosnjak B, Bernhardt G, et al. Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination. Cell Mol Immunol. 2021;18:2455–2456.

141. Schmidt T, Klemis V, Schub D, et al. Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nat Med. 2021;27:1530–1535.

142. Shaw RH, Stuart A, Greenland M, Liu X, Van-Tam JSN, Snape MD. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. Lancet. 2021;397:2043–2046.

143. He Q, Mao Q, An C, et al. Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates. Emerg Microbes Infect. 2021;10:630–637.

144. Spencer AJ, McKay PF, Beli-Rammerstorfer S, et al. Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice. Nat Commun. 2021;12:2893.

145. Gross R, Zanoni M, Seidel A, et al. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity [preprint]. medRxiv. 2021.